COMMUNIQUÉS West-GlobeNewswire

-
Profound Medical Announces Closing of Offerings
20/09/2019 - 15:13 -
Global Kinetics’ Personal KinetiGraph® (PKG®) Digital Wearable Technology Featured in Ten Posters at the International Congress of Parkinson’s Disease and Movement Disorders
20/09/2019 - 15:00 -
Melinda Rombouts Named a 2019 RBC Canadian Women Entrepreneur Award Recipient in the Ones to Watch Category
20/09/2019 - 14:45 -
Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer
20/09/2019 - 14:30 -
Novan Awarded Approximately $1.1 Million Grant by Department of Defense
20/09/2019 - 14:30 -
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
20/09/2019 - 14:30 -
XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies
20/09/2019 - 14:15 -
Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress
20/09/2019 - 14:00 -
Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference
20/09/2019 - 14:00 -
CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting
20/09/2019 - 14:00 -
GN announces changes to Executive Management
20/09/2019 - 13:40 -
Tauriga Sciences, Inc. Partners with LEAFBUYER Technologies Inc. to Enhance its Social Media Presence and Increase its E-Commerce Revenue
20/09/2019 - 13:32 -
TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
20/09/2019 - 13:30 -
MediPharm Labs Receives Organic Certification for Cannabis Oil and Extracts for Medical- and Adult-Use Markets
20/09/2019 - 13:02 -
Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815
20/09/2019 - 13:00 -
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis
20/09/2019 - 12:48 -
Sanofi : Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne sévère
20/09/2019 - 12:48 -
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0475 Per Share
20/09/2019 - 12:00 -
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
20/09/2019 - 09:05
Pages